Advanced Solid Tumors
Clinical research is centered on advanced solid tumors, with attention to treatment settings where disease control remains difficult and new therapeutic options are needed.
- Oncology
- Solid tumor malignancies
- Late-stage cancer treatment
The sponsor’s active programs in this area reflect interest in therapies for a broad range of refractory solid tumor indications.
DNA Damage Response Targeting
Research activity includes DNA damage response-focused oncology, an area aimed at exploiting vulnerabilities in cancer cells linked to genomic instability and repair pathways.
- Genome maintenance pathways
- Replication stress
- Targeted cancer therapeutics
This therapeutic domain is relevant to the development of precision approaches for tumors with repair-related dependencies.
Combination Cancer Therapy
The sponsor also investigates combination therapy strategies in advanced solid tumours, including regimens designed to integrate novel agents with established anticancer treatment backbones.
- Anticancer combinations
- Systemic therapy
- Treatment-resistant disease
These studies support exploration of therapeutic pairings for difficult-to-treat malignancies.
Clinical Pharmacology in Oncology
Clinical development efforts include pharmacokinetics, pharmacodynamics, and safety assessment in oncology populations, with emphasis on defining how investigational agents behave in patients with advanced cancer.
- Safety and tolerability
- Drug exposure
- Biological activity
These areas are central to establishing the therapeutic profile of new cancer treatments in clinical use.
